Ares Capital Corp (ARCC) 13.96 $ARCC Diversified

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Ares Capital Corp (ARCC) 13.96 $ARCC

Diversified Investments Stocks Review - Ares Capital, Nasdaq, Intercontinental Exchange, and FS Investment
PR Newswire - Tue Jun 28, 7:00AM CDT
On Monday, June 27, 2016, the NASDAQ Composite ended the trading session at 4,594.44, down 2.41%; the Dow Jones Industrial Average lost 1.50% to finish at 17,140.24; and the S&P 500 closed at 2,000.54, down 1.81%. Stock-Callers.com has initiated coverage on the following equities: Ares Capital Corporation (NASDAQ: ARCC), Nasdaq Inc. (NASDAQ: NDAQ), Intercontinental Exchange Inc. (NYSE: ICE), and FS Investment Corporation (NYSE: FSIC). Learn more about these stocks by accessing their free trade alerts at:
ARCC: 13.96 (-0.05), ICE: 256.89 (+2.93), NDAQ: 65.88 (+0.96), FSIC: 9.14 (-0.02)

Month-End Portfolio Data Now Available for Ares Dynamic Credit Allocation Fund, Inc.
BusinessWire - Wed Jun 22, 7:00AM CDT
Ares Capital Management II LLC today announced that monthly fund composition and performance data for Ares Dynamic Credit Allocation Fund, Inc. (NYSE:ARDC) as of May 31, 2016 is now available via www.arespublicfunds.com.
ARCC: 13.96 (-0.05), ARES: 15.37 (+0.60), ARDC: 13.98 (+0.15)

Ares Management Closes Third European Direct Lending Fund
BusinessWire - Fri Jun 10, 5:30AM CDT
Ares Management, L.P. (NYSE:ARES) announced today the final closing of its third European direct lending fund, Ares Capital Europe III ("ACE III". Approximately one year after its launch, ACE III was oversubscribed and closed at its hard cap of EUR2.5 billion, above its initial target of EUR2.0 billion. The fund attracted strong backing from a diverse group of existing and new investors globally, including pension funds, insurance companies, sovereign wealth funds, endowments, a private banking platform and family offices.
ARCC: 13.96 (-0.05), ARES: 15.37 (+0.60)

CORRECTING and REPLACING Ares Capital Corporation to Lead First $1 Billion Unitranche Credit Facility to Support Thoma Bravo's Acquisition of QLIK Technologies
BusinessWire - Thu Jun 02, 10:29AM CDT
First paragraph, fourth sentence of release should read: Other lead joint arrangers include Golub Capital LLC, TSSP and Varagon Capital Partners, LP (instead of Other lead joint arrangers include Golub Capital LLC, TPG Specialty Lending, Inc. and Varagon Capital Partners, LP.).
ARCC: 13.96 (-0.05), QLIK: 30.04 (+0.08), ARES: 15.37 (+0.60), TSLX: 17.10 (-0.01)

Ares Capital Corporation to Lead First $1 Billion Unitranche Credit Facility to Support Thoma Bravo's Acquisition of QLIK Technologies
BusinessWire - Thu Jun 02, 8:34AM CDT
Ares Capital Corporation (NASDAQ: ARCC) announced today that it is serving as the administrative agent, joint lead arranger and joint bookrunner for a $1.075 billion unitranche credit facility in support of the acquisition of Qlik Technologies, Inc. (NASDAQ: QLIK) by Thoma Bravo, a leading private equity firm. Ares Capital is committing to and holding a large portion of the financing, which is the largest unitranche financing by a business development company to date. In addition, Ares Capital will be leading the syndication process to attract additional lenders to the credit facility. Other lead joint arrangers include Golub Capital LLC, TPG Specialty Lending, Inc. and Varagon Capital Partners, LP. The transaction is expected to close late in the third quarter, subject to customary closing conditions, including investor and regulatory approvals.
ARCC: 13.96 (-0.05), QLIK: 30.04 (+0.08), ARES: 15.37 (+0.60), TSLX: 17.10 (-0.01)

Qlik Announces Agreement to be Acquired by Thoma Bravo for $30.50 Per Share
BusinessWire - Thu Jun 02, 7:30AM CDT
--Purchase Price Represents 40% Premium to Unaffected Stock Price
ARCC: 13.96 (-0.05), QLIK: 30.04 (+0.08)

Ares Management, L.P. Announces Pricing of $275 Million in Preferred Units
BusinessWire - Thu Jun 02, 5:30AM CDT
Ares Management, L.P. (NYSE:ARES) today announced the pricing of a $275 million offering of 11,000,000 of its 7.00% Series A Preferred Units representing limited partner interests with a liquidation preference of $25.00 per unit. In addition, Ares has granted the underwriters an option to purchase up to an additional 1,650,000 Series A Preferred Units solely to cover over-allotments.
ARCC: 13.96 (-0.05), ARES: 15.37 (+0.60)

Fitch Expects to Rate Ares Management, L.P.'s Preferred Issuance 'BBB-'
BusinessWire - Wed Jun 01, 12:09PM CDT
Fitch Ratings expects to rate Ares Management, L.P.'s (Ares) perpetual preferred issuance 'BBB-'.
ARCC: 13.96 (-0.05)

Milberg LLP Announces Investigation of Board of Directors' Decision to Sell American Capital, Ltd. to Ares Capital Corporation
PR Newswire - Tue May 31, 4:20PM CDT
Milberg LLP is investigating possible breaches of fiduciary duty and other violations of law in connection with the proposed acquisition of American Capital, Ltd. (ACAS) ("American Capital" or the "Company" to Ares Capital Corporation (ARCC) ("Ares".
ACAS: 15.86 (unch), ARCC: 13.96 (-0.05), AGNC: 19.24 (-0.25)

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Announces the Investigation of American Capital, Ltd. (ACAS) Over the Proposed Sale of the Company to Ares Capital Corp.
BusinessWire - Thu May 26, 4:01PM CDT
Juan E. Monteverde, a partner at Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of American Capital, Ltd. ("American Capital" or the "Company" (Nasdaq:ACAS) for potential breaches of fiduciary duties in connection with the sale of the Company to Ares Capital Corp. for approximately $3.43 billion.
ACAS: 15.86 (unch), ARCC: 13.96 (-0.05)

SHAREHOLDER ALERT: Brower Piven Commences an Investigation into the Proposed Sale of American Capital Ltd. and Encourages Investors to Contact the Firm for Additional Information
BusinessWire - Tue May 24, 9:10PM CDT
The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by the Board of Directors of American Capital, Ltd. (Nasdaq: ACAS) ("American Capital" or the "Company" relating to the proposed buyout of American Capital by Ares Capital Corp. ("Ares"
ACAS: 15.86 (unch), ARCC: 13.96 (-0.05)

AMERICAN CAPITAL, LTD. SHAREHOLDER ALERT: Former SEC Attorney Willie Briscoe and Powers Taylor LLP Believe the Acquisition by Ares Capital Corporation May be Unfair to Shareholders
BusinessWire - Tue May 24, 1:33PM CDT
Former United States Securities and Exchange Commission attorney Willie Briscoe and the securities litigation firm of Powers Taylor LLP are investigating potential claims against the Board of Directors of American Capital, Ltd. ("American Capital" (NASDAQ: ACAS) concerning the acquisition by Ares Capital Corporation. Under the terms of the agreement, valued at approximately $3.43 billion, American Capital shareholders will only receive $8.86 cash and 0.483 shares of Ares Capital per American Capital share owned. The consideration is valued at $17.40 per share, which is significantly lower than at least one analyst's estimated value of $18.00.
ACAS: 15.86 (unch), ARCC: 13.96 (-0.05)

SHAREHOLDER ALERT: Pomerantz LLP Investigates Claims That the Merger May Not Be in the Best Interest of Investors of American Capital Ltd. - ACAS
PR Newswire - Tue May 24, 11:35AM CDT
Pomerantz LLP is investigating claims on behalf of investors of American Capital Ltd. ("American Capital" or the "Company" (NASDAQ: ACAS) (ISIN: US0250341038) (CUSIP: 025034103) concerning the proposed acquisition of American Capital by Ares Capital Corporation ("Ares Capital".
ACAS: 15.86 (unch), ARCC: 13.96 (-0.05)

AMERICAN CAPITAL INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of American Capital, Ltd.
PR Newswire - Tue May 24, 10:57AM CDT
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ("KSF" are investigating the proposed sale of American Capital, Ltd. ("ACAS" or the "Company" (NASDAQ: ACAS) to Ares Capital Corporation (NASDAQ: ARCC). Under the terms of the proposed transaction, shareholders of ACAS will receive a combination of cash and stock valued at approximately $17.40 for each share of ACAS that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
ACAS: 15.86 (unch), ARCC: 13.96 (-0.05)

American Capital to Sell Operations; Moody's Upgrade Likely
Zacks Equity Research - Zacks Investment Research - Tue May 24, 8:00AM CDT
Putting an end to all speculations about possible sale or restructuring, American Capital, Ltd. (ACAS) announced the sale of operations for $4 billion through two separate deals
ACAS: 15.86 (unch), GS: 150.38 (+3.38), ARCC: 13.96 (-0.05), AGNC: 19.24 (-0.25)

Monsanto gains on offer from Bayer; Tribune plunges
AP - Mon May 23, 3:33PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily Monday:
CI: 129.60 (+2.60), ANTM: 132.15 (+2.71), TPUB: 13.96 (+0.17), ARCC: 13.96 (-0.05), MON: 102.68 (+2.04), CF: 24.86 (+1.36), ANTX: 44.99 (+0.49), TLRD: 13.24 (+0.47)

Robbins Arroyo LLP: Acquisition of American Capital, Ltd. (ACAS) by Ares Capital Corporation (ARCC) May Not Be in Shareholders' Best Interests
BusinessWire - Mon May 23, 2:39PM CDT
Shareholder rights attorneys at Robbins Arroyo LLP are investigating the proposed acquisition of American Capital, Ltd. (NASDAQ: ACAS) by Ares Capital Corp. (NASDAQ: ARCC). On May 23, 2016, the two companies announced the signing of a definitive merger agreement pursuant to which Ares Capital will acquire American Capital. Under the terms of the agreement, American Capital shareholders will receive $8.86 in cash and 0.483 shares of Ares Capital for each share of American Capital they own, the value of which is equivalent to $17.40 per share of American Capital.
ACAS: 15.86 (unch), ARCC: 13.96 (-0.05)

Fitch Affirms Ares Capital's Ratings Following ACAS Purchase Announcement; Outlook Stable
BusinessWire - Mon May 23, 1:52PM CDT
Fitch Ratings has affirmed Ares Capital Corporation's (Ares) Long-Term Issuer Default Rating (IDR) and secured and unsecured debt ratings at 'BBB' following the announced acquisition of American Capital, Ltd. (ACAS). The Rating Outlook is Stable. A full list of rating actions follows at the end of this release.
ARCC: 13.96 (-0.05)

After Yesterday's Decline of 3.95%, Ares Capital Offers Investors Better Value
Comtex SmarTrend(R) - Mon May 23, 1:05PM CDT
Ares Capital (NASDAQ:ARCC) traded in a range yesterday that spanned from a low of $14.52 to a high of $14.99. Yesterday, the shares fell 3.9%, which took the trading range below the 3-day low of $14.96 on volume of 4.7 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
ARCC: 13.96 (-0.05)

Fitch Revises American Capital to Watch Positive on Announced Ares Acquisition
BusinessWire - Mon May 23, 1:00PM CDT
Fitch Ratings has revised the Rating Watch for American Capital, Ltd.'s (ACAS; 'BB-' to Positive from Negative following ACAS's announced sale to Ares Capital Corporation (ARCC; 'BBB', Outlook Stable) for approximately $3.43 billion. Approximately $887 million of ACAS's outstanding debt, as of March 31, 2016, is affected by this rating action. A complete list of ratings follows this release.
ARCC: 13.96 (-0.05)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

BioVid Debuts AI to Mimic Physician Decision-Making

Updated Category News Views 47

Revolutionizing Understanding: BioVid Mimetics™ Now here's something that's shaking the research tree: BioVid's launching Mimetics™, and it's a big deal. They've come up with AI that can mirror how physicians think and decide. This ain't your run-of-the-mill tech stuff—it's groundbreaking in understanding physician decision-making. The Core: How Do Doctors Really...

Continue Reading
Acqualina Resort's Sustainable Commitment Earns Praise

Updated Category News Views 52

Sustainability at the Heart of Luxury Spotlight's on Acqualina Resort again. The folks there have snagged the 2026 VERIFIED™ Responsible Hospitality badge from Forbes Travel Guide for the third straight year. Means they’re more than just a pretty face down in Miami. This accolade puts them slap bang among the best in sustainable luxury. Forbes doesn’t just hand...

Continue Reading
Divorce Expertise: Obenhaus Adds CDFA Credential

Updated Category News Views 84

Divorce isn't just a legal tangled mess; it's a financial minefield as well. Lindsey Obenhaus from Goranson Bain Ausley has beefed up her credentials with a Certified Divorce Financial Analyst® (CDFA®) designation, lending a sharper edge to her approach in divorce financials. When relationships turn sour, so do wallets, and Obenhaus aims to soften that blow for her...

Continue Reading
Howard Hughes Joins S&P SmallCap 600, Arcosa Out

Updated Category News Views 45

Shakeup in the S&P SmallCap 600 It’s one of those days where something shifts in the market landscape—Howard Hughes Holdings Inc. (NYSE: HHH) is swaggering into the S&P SmallCap 600. Kicking off on October 28, it's got quite the entrance lined up. On the other end, Arcosa Inc. (NYSE: ACA) is making a hasty exit after getting scooped up by CRH plc (NYSE: CRH). For...

Continue Reading
Darden Faces Class Action Over Reimbursement Failures

Updated Category News Views 15

Class Action Puts Darden Restaurants in Legal Hot Seat Darden Restaurants, Inc. is staring down the barrel of a lawsuit that's as fiery as a grill on a Saturday night rush. The legal cavalry from Blumenthal Nordrehaug Bhowmik De Blouw LLP has stormed in with a class action complaint, aiming dead center at Darden for allegedly breaching the California Labor Code. In plain...

Continue Reading
Amy Johnson Steps Up as GDIT President Amid Shifts

Updated Category News Views 68

A New Chapter for GDIT with a Veteran Leader Big shoes to fill? Nah, more like Amy Johnson was made for these shoes. Stepping up as president of General Dynamics Information Technology (GDIT) on November 3, she’s got 27 years of experience under her belt, all from General Dynamics' own backyard. This ain't her first rodeo. From tightrope-walking the perils of defense...

Continue Reading
Taiwan Fuses Ancient TCM with Modern Bio Tech in 2026

Updated Category News Views 40

The Dynamic Fusion of Heritage and Innovation When you think about it, mixing centuries-old herbal wisdom with today's cutting-edge biotech might sound like a plot twist, but that's exactly what's cooking in Taiwan. Over at SupplySide Global 2026 in Las Vegas, Taiwan's got something more than just traditional medicine to flaunt; it's showcasing an impressive fusion of...

Continue Reading
Think Together Marks 20 Years of ASES Impact in CA

Updated Category News Views 64

Hands-on Learning: California's Bright Future Starts Here Who's ever thought a schoolyard's the same after three? Let me tell you, in California, it's staying alive and kicking, thanks to Think Together's whirlwind of celebrations for the After School Education and Safety (ASES) program. We're talking 450 schoolyard shindigs highlighting not just how far expanded learning...

Continue Reading
University of Phoenix Unveils Credit for Prior Learning Advantages

Updated Category News Views 27

Navigating College Credits with Life Experience If you think school is the only place to pick up education that counts, think again. University of Phoenix is challenging this by recognizing the value of the hustle and grind working adults go through. During the recently wrapped-up National Transfer Student Week, Devin Andrews, their VP of Admissions and Evaluation, shed...

Continue Reading
Amgen's IMDELLTRA® Shows Promise in SCLC Battle

Updated Category News Views 142

Breakthrough Results in SCLC Treatment For years, small cell lung cancer (SCLC) has been the unruly beast in the oncology world, defying treatment advances and keeping survival rates stubbornly low. This nasty foe might just have met its match, folks. Amgen (NASDAQ:AMGN) announced results from their Phase 3 DeLLphi-305 trial that show their drug IMDELLTRA®, when teamed...

Continue Reading

Top 5 Most Recently Viewed Articles

VERSES AI Secures Major Contract with Global Investment Firm

Updated Category News Views 183

Strategic Move by VERSES AI VERSES AI Inc. has made an impressive leap in the cognitive computing sector by securing a contract with a leading global investment firm. This partnership is rooted in the recent success of the company's Genius beta program, where initial evaluations highlighted the platform's remarkable capabilities. Enterprise Agreement Details As part of...

Continue Reading
Expected Growth of Agricultural Adjuvants Market to USD 6.2B

Updated Category News Views 143

The Agricultural Adjuvants Market: An Overview The Agricultural Adjuvants Market is witnessing remarkable growth as demand for crop protection products increases. Recent studies estimate that the market, valued at around USD 3.9 billion, is projected to reach approximately USD 6.2 billion by 2034. This translates to a compound annual growth rate (CAGR) of about 4.78% from...

Continue Reading
Understanding CVS Health Inc.'s P/E Ratio in Depth

Updated Category News Views 428

Analyzing the Price-to-Earnings Ratio of CVS Health Inc. In the current trading session, CVS Health Inc. (NYSE: CVS) is trading at a price of $79.86, experiencing a slight decrease of 0.01%. Over the past month, the stock has shown a decline of about 0.99%. However, looking back over the last year, the company's stock has seen a remarkable increase of 44.98%. This...

Continue Reading
Lead the Charge: Edwards Lifesciences Shareholders Unite

Updated Category News Views 138

Understanding the Class Action for Edwards Lifesciences Investors If you are an investor in Edwards Lifesciences Corporation (NYSE: EW), it is crucial to be aware of your rights and options, especially in the wake of substantial losses. Recent developments have opened the door for investors to come together and pursue a collective legal approach toward holding the company...

Continue Reading
Johnson Fistel Investigates Centuri's Stock Price Decline

Updated Category News Views 46

Investigating Centuri Holdings, Inc. Johnson Fistel, LLP, a well-regarded shareholder rights law firm, has initiated an investigation into Centuri Holdings, Inc. (NYSE: CTRI) following a noteworthy decline in the company’s stock price. The firm is examining whether there were any violations of securities laws by the company's executives who may have misrepresented or...

Continue Reading